Carbapenems Versus Piperacillin-Tazobactam for Bloodstream Infections of Nonurinary Source Caused by Extended-Spectrum Beta-Lactamase–Producing Enterobacteriaceae

Impact of Renal Function on the Pharmacokinetics and Safety of Ceftolozane-Tazobactam

(2014) Myra Wooley et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Impact of the MIC of Piperacillin-Tazobactam on the Outcome of Patients with Bacteremia Due to Extended-Spectrum-β-Lactamase-Producing Escherichia coli

(2013) Pilar Retamar et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Escherichia coli belonging to the worldwide emerging epidemic clonal group O25b/ST131: risk factors and clinical implications

(2013) L. Lopez-Cerero et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Efficacy of Ertapenem for Treatment of Bloodstream Infections Caused by Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae

(2012) Vicki L. Collins et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Impact of Cefepime Therapy on Mortality among Patients with Bloodstream Infections Caused by Extended-Spectrum-β-Lactamase-Producing Klebsiella pneumoniae and Escherichia coli

(2012) Teena Chopra et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Community-Associated Extended-Spectrum β-Lactamase–Producing Escherichia coli Infection in the United States

(2012) Yohei Doi et al.   CLINICAL INFECTIOUS DISEASES

Extended-Spectrum β-Lactamase Producers Reported as Susceptible to Piperacillin-Tazobactam, Cefepime, and Cefuroxime in the Era of Lowered Breakpoints and No Confirmatory Tests

(2012) Dror Marchaim et al.   INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY

Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum  -lactamases: a systematic review and meta-analysis

(2012) K. Z. Vardakas et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

 -Lactam/ -Lactam Inhibitor Combinations for the Treatment of Bacteremia Due to Extended-Spectrum  -Lactamase-Producing Escherichia coli: A Post Hoc Analysis of Prospective Cohorts

(2011) J. Rodriguez-Bano et al.   CLINICAL INFECTIOUS DISEASES

Can We Really Use ss-Lactam/ss-Lactam Inhibitor Combinations for the Treatment of Infections Caused by Extended-Spectrum ss-Lactamase-Producing Bacteria?

(2011) F. Perez et al.   CLINICAL INFECTIOUS DISEASES

The effects of group 1 versus group 2 carbapenems on imipenem-resistant Pseudomonas aeruginosa: an ecological study

(2011) Yehuda Carmeli et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

National Multicenter Study of Predictors and Outcomes of Bacteremia upon Hospital Admission Caused by Enterobacteriaceae Producing Extended-Spectrum  -Lactamases

(2010) D. Marchaim et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Three Decades of  -Lactamase Inhibitors

(2010) S. M. Drawz et al.   CLINICAL MICROBIOLOGY REVIEWS

Hospital-Acquired Infections Due to Gram-Negative Bacteria

(2010) Anton Y. Peleg et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Multinational Survey of Risk Factors for Infection with Extended‐Spectrum β‐Lactamase–Producing Enterobacteriaceae in Nonhospitalized Patients

(2009) Ronen Ben‐Ami et al.   CLINICAL INFECTIOUS DISEASES

Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008

(2009) R Phillip Dellinger et al.   CRITICAL CARE MEDICINE

CDC/NHSN surveillance definition of health care–associated infection and criteria for specific types of infections in the acute care setting

(2008) Teresa C. Horan et al.   AMERICAN JOURNAL OF INFECTION CONTROL

Extended-spectrum β-lactamases in North America, 1987–2006

(2008) K. Bush   CLINICAL MICROBIOLOGY AND INFECTION